• Title/Summary/Keyword: Severe Acute Respiratory Syndrome

Search Result 299, Processing Time 0.026 seconds

Lung Transplantation for Patients with COVID-19 Acute Respiratory Distress Syndrome

  • Cho, Woo Hyun
    • Journal of Chest Surgery
    • /
    • v.55 no.4
    • /
    • pp.357-360
    • /
    • 2022
  • Patients with severe coronavirus disease 2019 (COVID-19) acute respiratory distress syndrome (ARDS) may exhibit pulmonary fibrosis after the viral illness resolves. Some of these patients may experience severe functional lung impairment, and thus require transplants to prevent death or maintain a tolerable quality of life. Considering the reversibility of COVID-19 ARDS, lung transplant candidates are observed for 1-2 months and must be selected very carefully before transplantation. As the short-term outcomes of such patients are comparable to those of patients with other indications for transplantation, lung transplantation should be actively considered.

Development of Reverse Transcriptase Polymerase Chain Reaction Primer Sets and Standard Positive Control Capable of Verifying False Positive for the Detection of Severe acute respiratory syndrome coronavirus 2

  • Cho, Kyu Bong
    • Biomedical Science Letters
    • /
    • v.27 no.4
    • /
    • pp.283-290
    • /
    • 2021
  • Severe acute respiratory syndrome coronavirus (SARS-CoV2) is a major coronavirus that infects humans with human Coronavirus (HuCoV)-229E, HCoV-OC43, HCoV-HKU1, HCoV-NL63, Severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle east respiratory syndrome coronavirus (MERS-CoV). SARS-CoV2 is currently a global pandemic pathogen. In this study, we developed conventional RT-PCR based diagnostic system for the detection of SARS-CoV2 which is relatively inexpensive but has high stability and a wide range of users. Three conventional RT-PCR primer sets capable of forming specific band sizes by targeting the ORF1ab [232 nucleotide (nt)], E (200 nt) and N (288 nt) genes of SARS-CoV2 were developed, respectively, and it were confirmed to be about 10~100 times higher detection sensitivity than the previously reported methods. In addition, a standard positive control that can generate specific amplicons by reacting with the developed RT-PCR primers and verify the false-positiv from contamination of the laboratory was produced. Therefore, the diagnostic system that uses the RT-PCR method is expected to be used to detect SARS-CoV2.

An Overview on the Traditional Chinese Medicine Treatment Guidelines for Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS) (중증급성호흡기증후군(SARS) 및 중동호흡기증후군(MERS)의 중의 진료지침에 대한 고찰)

  • Ryu, Han-sung;Oh, Hye-kyung;Lee, Jee-young;Yoon, Seong-woo
    • The Journal of Internal Korean Medicine
    • /
    • v.36 no.3
    • /
    • pp.335-347
    • /
    • 2015
  • Objectives This study aims to overview traditional Chinese medicine (TCM) treatment guidelines for severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) in order to facilitate the use of Korean medicine (KM) treatment in pandemic diseases. Methods We compared the characteristics between SARS and MERS, and overviewed the Traditional Chinese Medicine treatment guidelines for SARS and MERS. We assessed the efficacy of simultaneous administration of herbal medicine and Western medicine on SARS by studying Cochranes 2012's Systematic Review Studies. Results and Conclusions Based on wen bing (warm diseases) of KM as well as TCM, KM treatment can be an alternative for pandemic diseases such as SARS and MERS considering the Korean's characteristic environment.

A Statistical Model for Severe Acute Respiratory Syndrome

  • Hong, Yeon-Woong
    • Journal of the Korean Data and Information Science Society
    • /
    • v.14 no.3
    • /
    • pp.615-622
    • /
    • 2003
  • The severe acute respiratory syndrome(SARS) is a novel infectious disease with global impact. The rapid worldwide spread of SARS has led to 30 countries reporting cases of July 13, 2003. In this paper, we develop a statistical model for SARS-caused-death data under some assumptions. The model developed is a continuous time Markov process with a constant intensity for each stage.

  • PDF

Epidemiology, virology, and clinical features of severe acute respiratory syndrome -coronavirus-2 (SARS-CoV-2; Coronavirus Disease-19)

  • Park, Su Eun
    • Clinical and Experimental Pediatrics
    • /
    • v.63 no.4
    • /
    • pp.119-124
    • /
    • 2020
  • A cluster of severe pneumonia of unknown etiology in Wuhan City, Hubei province in China emerged in December 2019. A novel coronavirus named severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) was isolated from lower respiratory tract sample as the causative agent. The current outbreak of infections with SARS-CoV-2 is termed Coronavirus Disease 2019 (COVID-19) by the World Health Organization (WHO). COVID-19 rapidly spread into at least 114 countries and killed more than 4,000 people by March 11 2020. WHO officially declared COVID-19 a pandemic on March 11, 2020. There have been 2 novel coronavirus outbreaks in the past 2 decades. The outbreak of severe acute respiratory syndrome (SARS) in 2002-2003 caused by SARS-CoV had a case fatality rate of around 10% (8,098 confirmed cases and 774 deaths), while Middle East respiratory syndrome (MERS) caused by MERS-CoV killed 861 people out of a total 2,502 confirmed cases between 2012 and 2019. The purpose of this review is to summarize known-to-date information about SARS-CoV-2, transmission of SARS-CoV-2, and clinical features.

Antiviral effect of fucoxanthin obtained from Sargassum siliquastrum (Fucales, Phaeophyceae) against severe acute respiratory syndrome coronavirus 2

  • Nalae Kang;Seong-Yeong Heo;Eun-A Kim;Seon-Heui Cha;Bomi Ryu;Soo-Jin Heo
    • ALGAE
    • /
    • v.38 no.4
    • /
    • pp.295-306
    • /
    • 2023
  • Human coronavirus diseases, particularly severe acute respiratory syndrome coronavirus 2, still remain a persistent public health issue, and many recent studies are focusing on the quest for new leads against coronaviruses. To contribute to this growing pool of knowledge and explore the available marine natural products against coronaviruses, this study investigated the antiviral effects of fucoxanthin isolated from Sargassum siliquastrum-a brown alga found on Jeju Island, South Korea. The antiviral effects of fucoxanthin were confirmed in severe acute respiratory syndrome coronavirus 2-infected Vero cells, and its structural characteristics were verified in silico using molecular docking and molecular dynamic simulations and in vitro colorimetric method. Fucoxanthin inhibited the infection in a concentration-dependent manner, without showing cytotoxicity. Molecular docking simulations revealed that fucoxanthin binds to the angiotensinconverting enzyme 2-spike protein (binding energy -318.306 kcal mol-1) and main protease (binding energy -205.118 kcal mol-1). Moreover, molecular dynamic simulations showed that fucoxanthin remains docked to angiotensin-converting enzyme 2-spike protein for 20 ns, whereas it breaks away from main protease after 3 ns. Also, the in silico prediction of the fucoxanthin was verified through the in vitro colorimetric method by inhibiting the binding between angiotensinconverting enzyme 2 and spike protein in a concentration-dependent manner. These results indicate that fucoxanthin exhibits antiviral effects against severe acute respiratory syndrome coronavirus 2 by blocking the entry of the virus. Therefore, fucoxanthin from S. siliquastrum can be a potential candidate for treating coronavirus infection.

Sepsis and Acute Respiratory Distress Syndrome: Recent Update

  • Kim, Won-Young;Hong, Sang-Bum
    • Tuberculosis and Respiratory Diseases
    • /
    • v.79 no.2
    • /
    • pp.53-57
    • /
    • 2016
  • Severe sepsis or septic shock is characterized by an excessive inflammatory response to infectious pathogens. Acute respiratory distress syndrome (ARDS) is a devastating complication of severe sepsis, from which patients have high mortality. Advances in treatment modalities including lung protective ventilation, prone positioning, use of neuromuscular blockade, and extracorporeal membrane oxygenation, have improved the outcome over recent decades, nevertheless, the mortality rate still remains high. Timely treatment of underlying sepsis and early identification of patients at risk of ARDS can help to decrease its development. In addition, further studies are needed regarding pathogenesis and novel therapies in order to show promising future treatments of sepsis-induced ARDS.

Epidemiology, Virology, and Clinical Features of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2; Coronavirus Disease-19) (코로나바이러스감염증-19의 바이러스 (SARS-CoV-2) 특징, 전파 및 임상 양상)

  • Park, Su Eun
    • Pediatric Infection and Vaccine
    • /
    • v.27 no.1
    • /
    • pp.1-10
    • /
    • 2020
  • A cluster of severe pneumonia of unknown etiology in Wuhan City, Hubei province in China emerged in December 2019. A novel coronavirus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was isolated from lower respiratory tract sample as the causative agent. The current outbreak of infections with SARS-CoV-2 is termed coronavirus disease 2019 (COVID-19) by the World Health Organization (WHO). COVID-19 rapidly spread into at least 114 countries and killed more than 4,000 people by March 11, 2020. WHO officially declared COVID-19 a pandemic on March 11, 2020. There have been 2 novel coronavirus outbreaks in the past 2 decades. The outbreak of severe acute respiratory syndrome (SARS) in 2002-2003 caused by SARS-CoV had a case fatality rate of around 10% (8,098 confirmed cases and 774 deaths), while Middle East respiratory syndrome (MERS) caused by MERS-CoV killed 858 people out of a total 2,499 confirmed cases between 2012 and 2019. The purpose of this review is to summarize known-to-date information about SARS-CoV-2, transmission of SARS-CoV-2, and clinical features of COVID-19.

Thrombosis and severe acute respiratory syndrome coronavirus 2 vaccines: vaccine-induced immune thrombotic thrombocytopenia

  • Park, Young Shil
    • Clinical and Experimental Pediatrics
    • /
    • v.64 no.8
    • /
    • pp.400-405
    • /
    • 2021
  • The development of vaccines against severe acute respiratory syndrome coronavirus 2, which features high mortality and morbidity rates, has progressed at an unprecedented rate, and vaccines are currently in use worldwide. Thrombotic events after vaccination are accompanied by thrombocytopenia, and this issue was recently termed vaccine-induced immune thrombotic thrombocytopenia. This manuscript describes recently published guidelines and other related issues and demonstrates characteristic cases.